<DOC>
	<DOCNO>NCT02111291</DOCNO>
	<brief_summary>The current trial examines potential benefit continuous 12 week treatment Santyl , measure term wound bed appearance . The visual appearance granulation tissue record visit purpose examine relationship wound bed appearance progress towards heal . In support longer treatment regimen Santyl , recent animal study find application Santyl 12 week safe well tolerate . Therefore , present study design test hypothesis daily treatment diabetic foot ulcer ( DFU ) Santyl 12 week result rapid development granulation tissue DFU treat supportive care .</brief_summary>
	<brief_title>Santyl Applications Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Subjects consider qualified enrollment meet follow criterion : 1 . Provide write informed consent , consist reading , signing , date informed consent document Investigator , subInvestigator designate study staff member explain study procedure , risk , contact information . 2 . Eighteen ( 18 ) year age old , either sex , race skin type provide skin color , opinion Investigator , interfere study assessment . 3 . Willing able make require study visit . 4 . Able follow instruction perform dress change home caregiver perform dressing change accord protocol . 5 . Willing use appropriate offloading device whenever necessary keep weight foot ulcer . 6 . An ulcer present part plantar surface foot plantar surface hallux 0.5 cm2 10 cm2 inclusive ( measure Screening Visit ) duration ≥ 6 week 52 week ( 12 month ) document patient 's history patient report onset require debridement . 7 . Adequate arterial blood flow evidence ankle brachial index ( ABI ) &gt; 0.70 ≤ 1.20 . If ABI &gt; 1.2 , perfusion near site ulcer confirm ; foot warm touch palpable pulse . 8 . Separation least 5 cm ( close ulcer edge close ulcer edge ) ≥ 2 ulcer present . 9 . Diabetes mellitus ( Type 1 2 ) require insulin oral/injectable medication control blood glucose level . 10 . Target ulcer infect base clinical assessment . Any one ( 1 ) follow criterion disqualify potential Subject participation study . 1 . Contraindications hypersensitivity use clostridial collagenase hydrogel . 2 . Undergoing therapy another investigational agent within thirty ( 30 ) day Visit 1 , plan participation overlap study . 3 . Bleeding disorder would preclude sharp debridement study . 4 . Active cellulitis target ulcer , lymphangitic streaking , deep tissue abscess , gangrene , infection muscle , tendon , joint bone . 5 . Infection systemic toxicity metabolic instability ( e.g. , fever , chill , tachycardia , hypotension , confusion , vomit , leukocytosis , acidosis , severe hyperglycemia , azotemia ) . 6 . A target ulcer involve underlie tissue tendon , muscle , bone . 7 . Diagnosis chronic granulomatous disease , leukocyte adhesion defect , severe neutropenia . 8 . Current treatment ( time Screening Visit ) following : Systemic corticosteroid . If corticosteroid treatment ≥ 10 day , must 1 week interval discontinuation screening . Immunosuppressive agent Chemotherapeutic agent Antiviral agent Systemic antibiotic therapy topical antibiotic treatment target ulcer 9 . Treatment target ulcer bioactive therapy within 1 month screening : Plateletderived growth factor ( e.g. , Regranex ) Living skin equivalent ( e.g. , Apligraf ) Dermal substitute ( e.g. , Dermagraft , Integra , Oasis , etc . ) 10 . Treatment target ulcer length time clostridial collagenase ointment ( SANTYL® ) within 12 week prior screen . 11 . Target ulcer fail develop wellestablished granulation tissue treat clostridial collagenase ointment ( SANTYL® ) least 4 week . 12 . Radiation therapy target low extremity within 30 day prior screen . 13 . Medical physical condition , opinion Investigator , would preclude safe subject participation study . 14 . Blood count blood chemistry value follow : Alanine aminotransferase ( ALT ) &gt; 3x upper limit normal Aspartate aminotransferase ( AST ) &gt; 3x upper limit normal Gamma Glutamyl Transferase ( GGT ) &gt; 2.5x upper limit normal Serum albumin &lt; 2.0 g/dL • Prealbumin level &lt; 10 mg/dL Alkaline phosphatase &gt; 500 U/L • Serum total bilirubin &gt; 3.0 mg/dL Serum BUN &gt; 75 mg/dL • Serum creatinine &gt; 4.5 mg/dL HbA1c &gt; 12 % • Hemoglobin ( Hgb ) &lt; 8.0 g/dL WBC &lt; 2.0 x 109/L • Absolute neutrophil count &lt; 1.0 x 109/L Platelet count &lt; 50 x 109/L • INR &gt; 1.5x upper limit normal Furthermore , prior randomization Visit 1 , follow exclusion criterion apply : 1 . Use excluded concomitant medication therapy Screening Visit 1 . 2 . A clinically diagnosed infection target ulcer require treatment . 3 . Muscle , tendon , bone exposure target ulcer . 4 . After debridement Visit 1 , ulcer area &gt; 12 cm2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diabetic Foot Ulcers</keyword>
</DOC>